nocturia in OAB patients.
HRQOL questionnaires can be classified as comprehensive or disease-specific. The SF-36 is a typical comprehensive questionnaire and it is used worldwide. The Medical Outcomes Study 8-item Short Form Health Survey (SF-8) is a short version of SF-36 that permits comparison of HRQOL between patients with various diseases or comparison of health between patients and the general population [9] . Compared with the SF-36, the SF-8 is more practical for evaluation of the actual condition of patients and their clinical response, in combination with other questionnaires, because of its simplicity. A prostate cancer-specific questionnaire, the Expanded Prostate Cancer Index Composite (EPIC), is recommended for use with comprehensive questionnaires. The SF-12, another short version of the SF-36, has often been employed with EPIC in overseas studies, while use of EPIC with the SF-8 has been verified in Japan [10] . For evaluating the influence of nocturia, however, the SF-8 has never been used by itself or in combination with other questionnaires.
In this study, we investigated the influence of nocturia and sleep disturbance on HRQOL using the SF-8, PSQI, and ESS in patients with nocturia, which was defined as one or more episodes of voiding per night (Study 1). We also assessed these parameters in patients who had nocturia associated with OAB before and after 12 weeks of treatment with an anticholinergic agent, imidafenacin, (Study 2).
METHODS

Influence of nocturia and sleep disturbance on HR-QOL (Study 1)
This study was performed at the Departments of Urology and Psychiatry of Kurume University and related hospitals in Japan in accordance with the Helsinki Declaration after approval of the Kurume University Ethics Committee. During the period between March 2009 and November 2011, patients with nocturia (at least one voiding episode per night) were enrolled after they gave informed consent (Fig. 1) .
One hundred and eighty-four patients were surveyed using a questionnaire prepared for this study that included the OABSS [11] , SF-8 [9] , Pittsburgh Sleep Quality Index (PSQI) [12] , and Epworth Sleepiness Scale (ESS) [13] .
HRQOL was evaluated by the SF-8, which includes 8 subscales ('physical functioning (PF)', 'role physical (RP)', 'bodily pain (BP)', 'general health (GH)', 'vitality (VT)', 'social functioning (SF)', 'role emotional (RE)', and 'mental health (MH)'), and 2 summary scores ('physical health component summary score (PCS)' and 'mental health component summary score (MCS)') that are calculated from the 8 subscale scores. In this study, the score for each subscale, the PCS, and the MCS were calculated using a normbased scoring method based on the national standard values determined from large-scale survey data for the general Japanese population (the mean score and standard deviation of the general Japanese population are 50 and 10, respectively) [9] .
For evaluation of sleep disturbance, the global and component scores of the PSQI and the total score of the ESS were investigated. Cut-off values of 5.5 for the PSQI [14] and 11 for the ESS [13] have been established as defining the presence/absence of sleep disturbance. 
HRQOL in OAB patients with nocturia treated with an anticholinergic agent (Study 2)
Study 2 was performed in 51 patients with OAB who met the inclusion criteria for Study 1 and did not fit either of the exclusion criteria (Fig. 1 ), which were a residual urine volume ＞ _ 100 mL and ineligibility for the study based on the judgment of the investigator.
Imidafenacin was administered at a dose of 0.1-0.2 mg twice daily (after breakfast and dinner) for 12 weeks. The effect of the drug was investigated at baseline and every 4 weeks during the treatment period using the OABSS, SF-8, PSQI, and ESS.
For statistical analysis, the Jonckheere-Terpstra trend test was used to evaluate the association between an increase of the OABSS nighttime voiding frequency score and parameters such as the SF-8, PSQI, and ESS scores. The Cochrane-Armitage trend test was employed to estimate the change in the percentage of patients with a PSQI global score or ESS total score higher than each cut-off value. The Wilcoxon signed-rank test or McNemar test was applied to compare the parameters at each time of assessment during treatment with those at baseline. In all analyses, p<0.05 was considered to indicate significance.
RESULTS
Influence of nocturia and sleep disturbance on HR-QOL (Study 1)
The patient characteristics are summarized in Table 1 . There were 184 patients (132 men and 52 women) with a mean age of 70.9±10.3 years. The most common underlying disease was OAB, which was diagnosed in 94 patients (51.1%). Among the male patients, 67 (50.8%) had benign prostatic hyperplasia (BPH). Other associated diseases included hypertension (22.3%) and diabetes (8.2%).
SF-8 scores stratified by the OABSS nighttime voiding frequency score are shown in Fig. 2 . The PCS showed a significant decrease as nocturia frequency increased. The MCS values were 47.1 and 47.6 (which were lower than the standard value of 50) in the groups with a nighttime voiding frequency score of 1 (once/ night group) and a score of 3 ( ＞ _3/night group), respectively. There was a negative association with an increasing frequency of nocturia for the PCS and 6 subscales of the SF-8 (PF, RP, GH, VT, SF, and MH).
The PSQI and ESS scores for nocturia are summarized in Table 2 . As nocturia increased, the PSQI global score showed a significant increase. In the ＞ _3/ night group, the mean score was 7.28, which exceeded the cut-off value of 5.5. Similarly, the PSQI component scores for 'sleep quality', 'sleep efficiency', and 'sleep disturbance' showed an increase, indicating that these items were significantly associated with the nighttime voiding frequency score. The percentage of patients with a PSQI global score ＞ _5.5 also increased and the association was significant. The ESS total score rose slightly with an increase of nocturia, but the change was not significant.
HRQOL in OAB patients with nocturia receiving treatment of an anticholinergic agent (Study 2)
The patient characteristics are listed in Table 3 . There were 51 patients (21 men and 30 women) with a mean age of 72.6±9.3 years. Thirteen male patients had BPH (61.9%). Other associated diseases were hypertension (37.3%), diabetes (13.7%), and cerebrovascular disease (9.8%).
Serial changes of the OABSS are summarized in Table 4 . Compared with the baseline value (2.61±0.67), Fig. 3 . The PCS was 39.5 before starting imidafenacin administration, and it increased to 42.3 (p=0.0713), 43.6 (p<0.05), and 42.5 (p=0.0618) after 4, 8, and 12 weeks of administration, respectively, with a significant difference between the baseline and 8-week scores. The MCS was 47.5 before administration and it increased significantly to 49.7 (p<0.05) and 50.1 (p<0.05) after 8 and 12 weeks, respectively. Regarding the subscales, significant improvement compared with baseline was found for RP at 8 weeks, BP and VT at 8, 12 weeks, MH at 4 and 8 weeks, and GH and RE at 4, 8, and 12 weeks.
Serial changes of the PSQI and ESS are summarized in Table 5 . The PSQI global score was 6.51±4.10 at baseline, whereas the score decreased to 5.42±3.33 (p=0.0503), 5.09±3.10 (p<0.01), and 5.44±3.22 (p=0.0793) at 4, 8, and 12 weeks, respectively, all of which were below the cut-off value of 5.5. In addition, the percentage of patients with a score>5.5 was 55.8% at baseline, but decreased to 37.2% (p<0.05), 37.2% (p<0.05), and 46.5% at 4, 8, and 12 weeks, respectively. The PSQI component scores for 'sleep quality' and 'sleep latency' were also significantly improved after 4, 8, and 12 weeks compared with those at baseline. Moreover, 'daytime dysfunction' showed significant improvement at 8 weeks. The ESS total score was also significantly improved at 4, 8, and 12 weeks compared with the baseline value. At baseline, 7.1% of patients had a score higher than the cut-off value of 11 and this percentage decreased to 2.4% after 4 weeks.
Regarding adverse events caused by imidafenacin therapy, anticholinergic adverse effects (dry mouth and constipation) were occasionally noted, but none of these became serious. 
DISCUSSION
While a negative influence of nocturia on HRQOL has been reported by many authors, few studies have evaluated the influence of nocturia and sleep disturbance on comprehensive HRQOL using the SF-8. This is the first study in which the SF-8 was employed to demonstrate that an increase of nighttime voiding frequency has a marked influence on not only sleep disturbance but also HRQOL in Japanese patients with nocturia. Since the SF-8 is a comprehensive QOL questionnaire, our findings indicate that nocturia influences both sleep and overall ADL.
A previous Dutch study using RAND-36 [3] showed that subjects who found nocturia to be bothersome were mentally and physically less healthy than those SF-8 SURVEY ON NOCTURIA AND SLEEP DISTURBANCE without nocturia. A Swedish study [15] using an original questionnaire found that an increase of nocturia was associated with the impairment of both physical and mental health. Our findings support these reports as we showed that an increase in nighttime voiding frequency was associated with lower scores for the PCS and mental subscales (SF and MH) of the SF-8. Thus, an increase in nighttime voiding has a negative influence on both mental and physical health to some extent, showing that nocturia is not just a nocturnal problem. The SF-8 allows us to compare HRQOL between patients with different diseases and also to make international comparisons of diseases. In this study, patients who voided twice/night had a PCS of 44.7 and an MCS of 50.8, while those voiding ＞ _3 times/night had a PCS of 43.1 and an MCS of 47.6. These values are similar to or lower than those obtained in patients with diabetes (47.20 and 48.22, respectively), hypertension (48.33 and 49.32, respectively), and osteoarthritis (45.73 and 49.16, respectively) in a study performed in the US [16] , or those for outpatients with cancer (44.3 and 47.6, respectively) obtained in Japan [17] . It is noteworthy that our patients voiding ＞ _3 times/night had a very low PCS score, which was similar to that of cancer patients. This indicates that nocturia can seriously impair HRQOL and requires therapeutic intervention.
The results of our Study 1 showed that an increase of nighttime voiding frequency is associated with a deterioration of 'Sleep quality', rather than a decrease of 'Sleeping duration'. This is noteworthy since it suggests that a qualitative, rather than a quantitative factor, contributes to sleep disturbance caused by an increase of voiding. Waking up during the night to void impairs the continuation of sleep due to the influence of intermittent awakening. Thus, voiding causes difficulty in returning to sleep due to factors such as behavioral arousal, the effect of the light in the toilet, or stimulation by the low room temperature in winter. All of these factors can shorten the sleeping time and lead to lighter sleep. Intermittent awakening suppresses slow-wave sleep that is required for true recuperation of physiological function. Shortening of the sleeping time also negatively influences metabolic and endocrine functions [18] . Moreover, insufficient slow-wave sleep impairs the regulation of various biological hormones, even if the total sleeping time is maintained [19] , preventing recovery from fatigue and resting of the brain. Thus, nocturia-induced intermittent awakening may qualitatively and quantitatively impair sleep, as described above, and the present findings suggest that one mechanism underlying the negative influence of increased nighttime voiding on HRQOL is dysregulation of biological functions due to impaired sleep, particularly reduced sleep quality.
OAB is a cause of nocturia that is mainly treated by using anticholinergic agents. Intervention with such drugs may be useful for reducing nighttime voiding and several anticholinergic agents are currently available in Japan. Imidafenacin was released in Japan in 2007 [20, 21] . It is more bladder-selective compared with other drugs [22] , leading to mild anticholinergic adverse effects such as dry mouth and constipation [23] , along with good long-term (52 weeks) efficacy, safety, and tolerability [24, 25] in OAB patients. Because of these characteristics, imidafenacin is widely employed for the treatment of OAB in elderly Japanese patients. Use of imidafenacin to treat OAB accompanied by nocturia has also attracted attention, and the improvement of nocturia, sleep disturbance, and HRQOL have been reported [7, 8] . The effect of imidafenacin on nocturia with OAB has been established, so we monitored the change of SF-8 score after use of this anticholinergic agent as a medical intervention.
Treatment with imidafenacin significantly improved nocturia in the present study. Sleep disturbance was also improved according to the PSQI and ESS. Moreover, HRQOL was improved according to the SF-8 (PCS and MCS), which revealed either significant improvement or a tendency for improvement from 8 weeks. Similar findings have recently been reported by Nagaoka et al. [26] and Wada et al. [27] , who concluded that imidafenacin can be useful for the treatment of nocturia, sleep disturbance, and HRQOL.
In general, comprehensive scales are considered to be less appropriate for assessing the effect of medical intervention on specific diseases compared with disease-specific scales. However, a therapeutic effect of imidafenacin was detected in the present study by the SF-8, a comprehensive scale, which suggests that the SF-8 can be used to monitor HRQOL in OAB patients with nocturia receiving treatment with anticholinergics.
CONCLUSION
This is the first study using the SF-8 to show that nocturia and sleep disturbance have a major influence on comprehensive HRQOL, similar to that of other chronic disease such as diabetes, hypertension, and even cancer in outpatients, and that the SF-8 can be used to monitor HRQOL in OAB patients receiving treatment for nocturia.
